SGMT
Sagimet Biosciences Inc. NASDAQ Listed Jul 17, 2023$7.64
After hrs
$7.75
+0.52%
Mkt Cap $248.9M
52w Low $3.08
54.7% of range
52w High $11.41
50d MA $5.88
200d MA $6.77
P/E (TTM)
-4.8x
EV/EBITDA
-2.8x
P/B
2.2x
Debt/Equity
0.0x
ROE
-45.8%
P/FCF
-4.2x
RSI (14)
—
ATR (14)
—
Beta
3.21
50d MA
$5.88
200d MA
$6.77
Avg Volume
516.3K
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
155 Bovet Road · San Mateo, CA 94402 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | — | — | — | — | — | — | — | — |
| May 7, 2026 | BMO | — | — | — | 8.38 | -0.6% | -8.8% | — | — | — | — | — |
| Mar 11, 2026 | AMC | -0.43 | -0.29 | +32.6% | 5.74 | -2.1% | -7.0% | -9.2% | -10.5% | -9.6% | -15.3% | — |
| Nov 13, 2025 | AMC | -0.41 | -0.40 | +2.4% | 7.74 | -1.0% | +0.1% | +0.9% | +1.0% | +1.4% | -6.1% | — |
| Aug 13, 2025 | AMC | -0.52 | -0.32 | +38.5% | 9.58 | -1.8% | -9.5% | -19.9% | -21.2% | -27.9% | -25.1% | — |
| May 8, 2025 | AMC | -0.79 | -0.56 | +29.1% | 3.20 | +0.9% | +1.9% | +3.4% | -0.6% | -3.1% | +3.4% | — |
| Mar 12, 2025 | AMC | -0.65 | -0.50 | +23.1% | 3.51 | -0.3% | +0.0% | +6.6% | +7.7% | +9.7% | +9.7% | — |
| Nov 14, 2024 | AMC | -0.47 | -0.45 | +4.3% | 5.18 | -2.5% | -8.7% | -15.8% | -14.9% | -12.7% | -13.1% | — |
| Aug 14, 2024 | AMC | -0.34 | -0.25 | +26.5% | 2.47 | +5.3% | +11.7% | +11.3% | +14.2% | +22.7% | +24.7% | — |
| May 15, 2024 | AMC | -0.41 | -0.23 | +43.9% | 4.62 | +1.3% | +2.8% | +0.0% | +2.6% | +3.7% | +10.0% | — |
| Mar 25, 2024 | AMC | -0.58 | -0.78 | -34.5% | 5.22 | +0.6% | +0.2% | +9.8% | +3.8% | +0.2% | +0.4% | — |
| Nov 13, 2023 | AMC | -1.02 | -0.35 | +65.7% | 2.23 | +5.8% | +13.0% | +10.8% | +4.5% | +32.7% | +35.0% | — |
| Jul 14, 2023 | AMC | -0.50 | -35.80 | -7060.0% | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Guggenheim | Maintains | Buy → Buy | — | $8.75 | $8.75 | +0.0% | -1.7% | -8.2% | -13.0% | -9.7% | -11.8% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.53 | $5.77 | +4.3% | +3.8% | -3.4% | -5.8% | -7.1% | -6.1% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.23 | $6.80 | +9.1% | +5.3% | -2.4% | -12.7% | -10.9% | -12.5% |
| Nov 14 | Citizens | Maintains | Market Outperform → Market Outperform | — | $7.74 | $7.66 | -1.0% | +0.1% | +0.9% | +1.0% | +1.4% | -6.1% |
| Oct 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.98 | $6.99 | +0.1% | +2.6% | +4.4% | +4.7% | +5.2% | +4.7% |
| Jun 6 | Jones Trading | Maintains | Buy → Buy | — | $4.78 | $4.78 | +0.0% | +16.3% | +11.5% | +24.3% | +29.5% | +80.1% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.51 | $3.50 | -0.3% | +0.0% | +6.6% | +7.7% | +9.7% | +9.7% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $3.59 | +1.4% | -4.0% | -0.8% | -0.8% | +5.6% | +6.8% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.18 | $5.05 | -2.5% | -8.7% | -15.8% | -14.9% | -12.7% | -13.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.34 | $5.29 | -0.9% | -3.6% | -0.2% | +1.5% | +8.8% | +12.4% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $3.16 | +1.3% | +9.0% | +32.1% | +31.1% | +33.3% | +27.2% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.47 | $2.60 | +5.3% | +11.7% | +11.3% | +14.2% | +22.7% | +24.7% |
| Aug 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.47 | $2.60 | +5.3% | +11.7% | +11.3% | +14.2% | +22.7% | +24.7% |
| Jul 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $3.42 | $3.40 | -0.6% | -7.6% | -14.3% | -16.7% | -13.5% | -9.1% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.79 | $4.59 | -4.2% | -13.6% | -11.9% | -17.5% | -18.8% | -18.0% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.57 | -1.7% | +1.1% | +4.9% | +6.7% | +14.8% | +3.0% |
| Jun 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.65 | $4.57 | -1.7% | +1.1% | +4.9% | +6.7% | +14.8% | +3.0% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.72 | +0.4% | +2.6% | +10.0% | +16.4% | +14.9% | +13.4% |
| May 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.70 | $4.72 | +0.4% | +2.6% | +10.0% | +16.4% | +14.9% | +13.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.62 | $4.68 | +1.3% | +2.8% | +0.0% | +2.6% | +3.7% | +10.0% |
| May 16 | Goldman Sachs | Maintains | Buy → Buy | — | $4.62 | $4.68 | +1.3% | +2.8% | +0.0% | +2.6% | +3.7% | +10.0% |
| Mar 26 | Goldman Sachs | Maintains | Buy → Buy | — | $5.22 | $5.25 | +0.6% | +0.2% | +9.8% | +3.8% | +0.2% | +0.4% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.35 | $6.56 | +3.3% | +3.6% | -5.5% | -1.7% | +26.1% | +16.9% |
| Jan 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.42 | $18.42 | +0.0% | -4.9% | -11.9% | -23.9% | -42.1% | -42.5% |
| Jan 23 | Goldman Sachs | Maintains | Buy → Buy | — | $18.42 | $18.42 | +0.0% | -4.9% | -11.9% | -23.9% | -42.1% | -42.5% |
| Jan 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.82 | $15.00 | +119.9% | +170.1% | +156.7% | +138.0% | +105.6% | +56.5% |
| Dec 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.06 | $4.10 | +1.0% | +2.2% | -2.0% | -0.5% | -10.6% | -5.7% |
No insider trades available.
8-K · 1.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 1.01: Underwriting / Securities
Sagimet Biosciences secured $164.5 million in Series A funding through Leerink Partners, providing capital to advance its biopharmaceutical pipeline and operations.
Apr 28
8-K · 7.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 7.01: Regulation FD Disclosure
Sagimet Biosciences is updating its investor presentation materials for ongoing shareholder communications and roadshow meetings.
Apr 27
8-K · 7.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 7.01: Regulation FD Disclosure
Sagimet Biosciences disclosed updated investor presentation materials for ongoing meetings, suggesting management is actively communicating financial and operational updates to shareholders.
Apr 27
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A life sciences-focused executive with deep investment banking expertise joined one of these companies, potentially signaling strategic M&A activity or capital-raising plans ahead.
Mar 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Sagimet disclosed material information via press release and investor presentation on March 11, 2026, likely announcing clinical trial results or strategic developments that could significantly impact the biotech stock's valuation and investor sentiment.
Mar 11
8-K · 7.01
! Medium
Sagimet Biosciences Inc. Series A -- 8-K 7.01: Regulation FD Disclosure
Sagimet Biosciences announced positive Phase 3 results for ASC40 in acne treatment, potentially advancing the drug toward regulatory approval and supporting future commercialization efforts.
Feb 2
Data updated apr 27, 2026 1:00am
· Source: massive.com